Keyword: Sprout Pharmaceuticals
AMAG's female libido drug Vyleesi has just won FDA approval. But will it reach blockbuster state? Management and analysts have different opinions.
Now that former shareholders of Sprout have the company back in their hands, they’ve reinstalled a familiar face at the helm.
After paying $1 billion for Sprout and its controversial female libido pill Addyi, Valeant is giving up.
When Valeant bought Sprout and its controversial female libido drug Addyi, it agreed to a marketing blitz that would bring royalties to Sprout's former shareholders. Valeant bungled the job, those former investors say. And they’re taking their gripes to court.
Poor sales trajectory, check. Scale-back in marketing effort, check. What’s next for Valeant’s Addyi and its maker, Sprout? An impairment charge, if you ask Wells Fargo’s analysts--and a big one, at that.